» Articles » PMID: 30843931

A Proposed Inflammatory Score of Circulating Cytokines/Adipokines Associated with Resistant Hypertension, but Dependent on Obesity Parameters

Abstract

Background: There is evidence that subclinical systemic inflammation is present in resistant hypertension (RHTN).

Objective: The aim of the study was to develop an integrated measure of circulating cytokines/adipokines involved in the pathophysiology of RHTN.

Methods: RHTN (n = 112) and mild to moderate hypertensive (HTN) subjects (n=112) were studied in a cross-sectional design. Plasma cytokines/adipokines (TNF-alpha, interleukins [IL]-6, -8, -10, leptin and adiponectin) values were divided into tertiles, to which a score ranging from 1 (lowest tertile) to 3 (highest tertile) was assigned. The inflammatory score (IS) of each subject was the sum of each pro-inflammatory cytokine scores from which anti-inflammatory cytokines (adiponectin and IL-10) scores were subtracted. The level of significance accepted was alpha = 0.05.

Results: IS was higher in RHTN subjects compared with HTN subjects [4 (2-6) vs. 3 (2-5); p = 0.02, respectively]. IS positively correlated with body fat parameters, such as body mass index (r = 0.40; p < 0.001), waist circumference (r = 0.30; p < 0.001) and fat mass assessed by bioelectrical impedance analysis (r = 0.31; p < 0.001) in all hypertensive subjects. Logistic regression analyses revealed that IS was an independent predictor of RHTN (OR = 1.20; p = 0.02), independent of age, gender and race, although it did not remain significant after adjustment for body fat parameters.

Conclusion: A state of subclinical inflammation defined by an IS including TNF-alpha, IL-6, IL-8, IL-10, leptin and adiponectin is associated with obese RHTN. In addition, this score correlates with obesity parameters, independently of hypertensive status. The IS may be used for the evaluation of conditions involving low-grade inflammation, such as obesity-related RHTN. Indeed, it also highlights the strong relationship between obesity and inflammatory process.

Citing Articles

GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review.

Jarade C, Zolotarova T, Moiz A, Eisenberg M EClinicalMedicine. 2024; 75:102789.

PMID: 39246720 PMC: 11377134. DOI: 10.1016/j.eclinm.2024.102789.


A data-driven computational model for obesity-driven diabetes onset and remission through weight loss.

Yildirim V, Sheraton V, Brands R, Crielaard L, Quax R, Van Riel N iScience. 2023; 26(11):108324.

PMID: 38026205 PMC: 10665812. DOI: 10.1016/j.isci.2023.108324.


Evaluating the Potential of Linneo (Sacha Inchi) in Alleviating Cardiovascular Disease Risk Factors: A Mini Review.

Abd Rahman I, Hisam N, Aminuddin A, A Hamid A, Kumar J, Ugusman A Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004453 PMC: 10675584. DOI: 10.3390/ph16111588.


Twenty-four-hour ambulatory, but not clinic blood pressure associates with leptin in young adults with overweight or obesity: The African-PREDICT study.

van Niekerk E, Botha-Le Roux S, Mels C, Swanepoel M, Delles C, Welsh P Hypertens Res. 2023; 47(2):478-486.

PMID: 37872379 PMC: 10838765. DOI: 10.1038/s41440-023-01477-7.


Deletion of complement factor 5 amplifies glucose intolerance in obese male but not female mice.

Winn N, Patel V, Blair J, Rodriguez A, Garcia J, Yang T Am J Physiol Endocrinol Metab. 2023; 325(4):E325-E335.

PMID: 37610411 PMC: 10642989. DOI: 10.1152/ajpendo.00140.2023.


References
1.
Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, Friedman J . Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest. 1996; 97(9):2152-7. PMC: 507291. DOI: 10.1172/JCI118653. View

2.
Calhoun D, Jones D, Textor S, Goff D, Murphy T, Toto R . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51(6):1403-19. DOI: 10.1161/HYPERTENSIONAHA.108.189141. View

3.
Daniele G, Guardado Mendoza R, Winnier D, Fiorentino T, Pengou Z, Cornell J . The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol. 2013; 51(1):123-31. DOI: 10.1007/s00592-013-0543-1. View

4.
Enkhmaa B, Anuurad E, Zhang W, Kim K, Berglund L . Diverging trajectory patterns of systemic versus vascular inflammation over age in healthy Caucasians and African-Americans. Atherosclerosis. 2015; 239(2):509-515. PMC: 4361330. DOI: 10.1016/j.atherosclerosis.2015.02.023. View

5.
Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y . Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25):2473-6. DOI: 10.1161/01.cir.100.25.2473. View